Dr. Marcus Kostka is a highly experienced biotech industry expert. He is co-founder and CEO of iDEL Therapeutics GmbH. From 2019-2024 he was CEO at Abalos Therapeutics in Düsseldorf. Prior to joining Abalos, he held various roles at Boehringer Ingelheim, his latest position being Venture Fund Partner since 2014. In this role, he was board member in EtheRNA NV, Cardior Pharmaceutical, Aelin Therapeutics and Rewind Therapeutics.
During his board membership he participated in the successful exits like Rigontec GmbH. Before, he was responsible for external innovation as well as for international research collaborations as Director of External Innovation and Director of Corporate Research Networking, respectively. From 2006 – 2009 as R&D Project Leader, Marcus was leading project teams from preclinical development until clinical phase II studies in the various indications.
In 2013 he co-founded MODAG GmbH in the area of neurodegenerative diseases, where he still is Chairman of the Board. In 2021 this resulted in a co-development deal with Teva.
He joined Boehringer Ingelheim in 1996 in the area of Alzheimer´s disease research and, after a postdoc period, transitioned to the company’s Parkinson disease research group in Biberach as molecular biology Lab Head. Marcus holds a Diploma in Biology with focus on Genetics and Biochemistry from the Johannes Gutenberg University in Mainz, Germany.
